371 related articles for article (PubMed ID: 12970777)
1. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.
Shelton JG; Moye PW; Steelman LS; Blalock WL; Lee JT; Franklin RA; McMahon M; McCubrey JA
Leukemia; 2003 Sep; 17(9):1765-82. PubMed ID: 12970777
[TBL] [Abstract][Full Text] [Related]
2. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
[TBL] [Abstract][Full Text] [Related]
3. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells.
Shelton JG; Steelman LS; Lee JT; Knapp SL; Blalock WL; Moye PW; Franklin RA; Pohnert SC; Mirza AM; McMahon M; McCubrey JA
Oncogene; 2003 Apr; 22(16):2478-92. PubMed ID: 12717425
[TBL] [Abstract][Full Text] [Related]
4. Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells.
Shelton JG; Blalock WL; White ER; Steelman LS; McCubrey JA
Cell Cycle; 2004 Apr; 3(4):503-12. PubMed ID: 15004527
[TBL] [Abstract][Full Text] [Related]
5. Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism.
Hoyle PE; Moye PW; Steelman LS; Blalock WL; Franklin RA; Pearce M; Cherwinski H; Bosch E; McMahon M; McCubrey JA
Leukemia; 2000 Apr; 14(4):642-56. PubMed ID: 10764150
[TBL] [Abstract][Full Text] [Related]
6. Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells.
McCubrey JA; Lee JT; Steelman LS; Blalock WL; Moye PW; Chang F; Pearce M; Shelton JG; White MK; Franklin RA; Pohnert SC
Cancer Detect Prev; 2001; 25(4):375-93. PubMed ID: 11531015
[TBL] [Abstract][Full Text] [Related]
7. Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells.
Konopleva M; Shi Y; Steelman LS; Shelton JG; Munsell M; Marini F; McQueen T; Contractor R; McCubrey JA; Andreeff M
Cancer Res; 2005 Nov; 65(21):9962-70. PubMed ID: 16267021
[TBL] [Abstract][Full Text] [Related]
8. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells.
Shelton JG; Steelman LS; White ER; McCubrey JA
Cell Cycle; 2004 Mar; 3(3):372-9. PubMed ID: 14726697
[TBL] [Abstract][Full Text] [Related]
9. Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells.
McCubrey JA; Shelton JG; Steelman LS; Franklin RA; Sreevalsan T; McMahon M
Oncogene; 2004 Oct; 23(47):7810-20. PubMed ID: 15361836
[TBL] [Abstract][Full Text] [Related]
10. Effects of deregulated Raf activation on integrin, cytokine-receptor expression and the induction of apoptosis in hematopoietic cells.
Weinstein-Oppenheimer C; Steelman LS; Algate PA; Blalock WL; Burrows C; Hoyle PE; Lee JT; Moye PW; Shelton JG; Franklin R; McCubrey JA
Leukemia; 2000 Nov; 14(11):1921-38. PubMed ID: 11069028
[TBL] [Abstract][Full Text] [Related]
11. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
Bertrand FE; Steelman LS; Chappell WH; Abrams SL; Shelton JG; White ER; Ludwig DL; McCubrey JA
Leukemia; 2006 Jul; 20(7):1254-60. PubMed ID: 16642049
[TBL] [Abstract][Full Text] [Related]
12. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
13. Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK and p38 MAPK signaling.
Wang Z; Jiang C; Ganther H; Lü J
Cancer Res; 2001 Oct; 61(19):7171-8. PubMed ID: 11585751
[TBL] [Abstract][Full Text] [Related]
14. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
15. PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival.
Coutant A; Rescan C; Gilot D; Loyer P; Guguen-Guillouzo C; Baffet G
Hepatology; 2002 Nov; 36(5):1079-88. PubMed ID: 12395317
[TBL] [Abstract][Full Text] [Related]
16. Human alphaA- and alphaB-crystallins prevent UVA-induced apoptosis through regulation of PKCalpha, RAF/MEK/ERK and AKT signaling pathways.
Liu JP; Schlosser R; Ma WY; Dong Z; Feng H; Liu L; Huang XQ; Liu Y; Li DW
Exp Eye Res; 2004 Sep; 79(3):393-403. PubMed ID: 15336502
[TBL] [Abstract][Full Text] [Related]
17. Cytokine-induced phosphoinositide 3-kinase activity promotes Cdk2 activation in factor-dependent hematopoietic cells.
Henry MK; Nimbalkar D; Hohl RJ; Quelle FW
Exp Cell Res; 2004 Sep; 299(1):257-66. PubMed ID: 15302592
[TBL] [Abstract][Full Text] [Related]
18. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.
Steelman LS; Abrams SL; Shelton JG; Chappell WH; Bäsecke J; Stivala F; Donia M; Nicoletti F; Libra M; Martelli AM; McCubrey JA
Cell Cycle; 2010 Apr; 9(8):1629-38. PubMed ID: 20372086
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
20. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
